SUPERNUS PHARMACEUTICALS INC. - COMMON STOCK
38.40
07-February-25 15:45:00
15 minutes delayed
Stocks
-0.45
-1.16%
Today's range
38.14 - 38.92
ISIN
N/A
Source
NASDAQ
-
Supernus Announces Second Quarter 2024 Financial Results
06 Aug 2024 15:06:00 By Nasdaq GlobeNewswire
-
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
01 Aug 2024 15:30:11 By Nasdaq GlobeNewswire
-
23 Jul 2024 15:13:37 By Nasdaq GlobeNewswire
-
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
30 May 2024 15:25:33 By Nasdaq GlobeNewswire
-
23 May 2024 15:05:48 By Nasdaq GlobeNewswire
-
09 May 2024 15:05:39 By Nasdaq GlobeNewswire
-
Supernus Announces First Quarter 2024 Financial Results
08 May 2024 15:05:50 By Nasdaq GlobeNewswire
-
Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story
01 May 2024 07:00:32 By Nasdaq GlobeNewswire
-
24 Apr 2024 15:05:53 By Nasdaq GlobeNewswire
-
Supernus Provides Regulatory Update for SPN-830
08 Apr 2024 07:00:16 By Nasdaq GlobeNewswire
-
Supernus to Participate in Two Upcoming Investor Conferences
06 Mar 2024 15:30:50 By Nasdaq GlobeNewswire
-
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
28 Feb 2024 15:30:04 By Nasdaq GlobeNewswire
-
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
27 Feb 2024 15:05:33 By Nasdaq GlobeNewswire
-
13 Feb 2024 15:05:20 By Nasdaq GlobeNewswire
-
Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent
05 Feb 2024 07:30:39 By Nasdaq GlobeNewswire
-
Supernus Announces Third Quarter 2023 Financial Results
08 Nov 2023 15:05:44 By Nasdaq GlobeNewswire
-
Supernus to Participate in the Jefferies London Healthcare Conference
07 Nov 2023 15:30:42 By Nasdaq GlobeNewswire
-
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
02 Nov 2023 06:00:05 By Nasdaq GlobeNewswire
-
25 Oct 2023 15:15:32 By Nasdaq GlobeNewswire
-
16 Oct 2023 16:34:21 By Nasdaq GlobeNewswire